Lead Product(s): Remestemcel-L
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FDA clearance provides a pathway in the United States for use of remestemcel-L in patients with COVID-19 ARDS, under both expanded access compassionate use and in planned randomized controlled trial.